Drug Profile
CG 209
Alternative Names: CG209Latest Information Update: 28 Jan 2024
Price :
$50
*
At a glance
- Originator ConverGene
- Class Small molecules
- Mechanism of Action Dopamine D2 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Psychotic disorders
Most Recent Events
- 28 Jan 2024 No recent reports of development identified for research development in Psychotic-disorders in USA
- 03 Jan 2022 Preclinical development is ongoing in Psychotic disorders in USA (ConverGene pipeline, January 2022)
- 28 Feb 2021 No recent reports of development identified for research development in Psychotic-disorders in USA